Immunovant Inc

Immunovant’s batoclimab fails Phase‑3 thyroid eye disease trial, slashing stock and spotlighting the high risk of FcRn‑blocking immunotherapies.

Immunovant Inc. has announced promising results for its Graves’ disease treatment, achieving durable and treatment-free six-month remission in patients, marking a potential breakthrough in the treatment of this chronic autoimmune disorder.